Hypoxic ASCs-derived Exosomes Attenuate Colitis by Regulating Macrophage Polarization via miR-216a-5p/HMGB1 Axis
Inflammatory Bowel Diseases · 03.04.2023 · 29 (4) · 602-619
DOI: 10.1093/ibd/izac225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 26.10.2022. Verfasst von Wenwei Qian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Jinling Hospital, Medical School of Southeast University, Nanjing, PR China. Hauptthemen laut MEDLINE: Exosomes, HMGB1 Protein, MicroRNAs, Colitis. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Exosomes derived from mesenchymal stem cells have shown therapeutic effects for colitis. As a more clinically accessible resource, the therapeutic potential of exosomes from adipose-derived stem cells (ASCs) has not been fully elucidated, and whether hypoxia precondition could improve the therapeutic effect of ASC-derived exosomes in colitis remains elusive.
Methods
In this study, exosomes were derived from ASCs under normoxia (NExos) and hypoxia (HExos) and were identified by detecting their morphology, size distribution, and exosome surface markers. The concentration of inflammation-related cytokines was detected by ELISA, and macrophage phenotype–related genes were determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR), western blot, and immunofluorescence. A miRNA microarray sequencing analysis was conducted to confirm the differentially expressed miRNAs. Dextran sulfate sodium–induced colitis was employed as an in vivo assay.
Results
Administration of NExos alleviated inflammation by modulating the balance of macrophages both in cellular assays and in vivo experiments, and HExos showed higher therapeutic efficiency than NExos. The miR-216a-5p in HExos was significantly enriched and promoted macrophage M2 polarization through transfer to macrophages by exosomes. The miR-216a-5p was confirmed to target the 3’-UTR of HMGB1. Mechanistically, hypoxia-induced ASCs release miR-216a-5p in an exosomal way that induced macrophage M2 polarization by regulating the HMGB1/TLR4/NF-κB signaling pathway.
Conclusions
Exosomal miR-216a-5p released from hypoxia-prime ASCs showed higher therapeutic efficiency than NExos in experimental colitis by promoting the M2 macrophage phenotype, which indicated that hypoxia prime may represent a promising approach to optimizing the function of ASC-derived exosomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Jinling Hospital, Medical School of Southeast University, Nanjing, PR China.
- Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China.
- Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, PR China.
- Department of Endocrinology and Metabolism, the First Affiliated Hospital of Soochow University, Suzhou, PR China.
ORCID-Profile: Liangyu Huang, Zhen Guo, Yi Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Qian, W., Huang, L., Xu, Y., Lu, W., Wen, W., Guo, Z., Zhu, W., & Li, Y. (2023). Hypoxic ASCs-derived Exosomes Attenuate Colitis by Regulating Macrophage Polarization via miR-216a-5p/HMGB1 Axis. Inflammatory Bowel Diseases, 29(4), 602-619. https://doi.org/10.1093/ibd/izac225
Vancouver
Qian W, Huang L, Xu Y, Lu W, Wen W, Guo Z, et al. Hypoxic ASCs-derived Exosomes Attenuate Colitis by Regulating Macrophage Polarization via miR-216a-5p/HMGB1 Axis. Inflammatory Bowel Diseases. 2023;29(4):602-619. doi:10.1093/ibd/izac225
BibTeX
@article{Qian2023,
author = {Qian, Wenwei and Huang, Liangyu and Xu, Yihan and Lu, Wen and Wen, Weiwei and Guo, Zhen and Zhu, Weiming and Li, Yi},
title = {Hypoxic ASCs-derived Exosomes Attenuate Colitis by Regulating Macrophage Polarization via miR-216a-5p/HMGB1 Axis},
journal = {Inflammatory Bowel Diseases},
year = {2023},
volume = {29},
number = {4},
pages = {602--619},
doi = {10.1093/ibd/izac225}
}
EUVIMED